
    pis were unable to recruit any participants
  
['schizophrenia']
['vorinostat oral capsule group 1', 'vorinostat oral capsule group 2']

        Inclusion Criteria:

          -  Diagnosed with DSM-5 Schizophrenia

          -  Receiving stable dose pf clozapine (≥ 300 mg per day) for at least 6 months before
             entering the study

        Exclusion Criteria:

          -  Taking specific psychotropic medications (lamotrigine and valproic acid)

          -  Current or recent (12-months) substance use or induced disorder

          -  History of significant neurological or medical disorders

          -  Intellectual disability

          -  Known contraindications to the administration of vorinostat per product labeling

          -  Women currently pregnant, planning to become pregnant, or receiving hormone therapy
             and refusing any form of birth control
      